ALNY · Alnylam Pharmaceuticals, Inc. · Debt
$165.04
+8.39 (+5.36%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$22.11B
Shares
133.94M
Volume · Nov 13
3.59M
Avg daily vol (3M)
2.04M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-09-30 | USD 46,083,000 | 10-Q filed 2026-10-29 |
| Current portion of convertible debt | 2026-09-30 | USD 361,529,000 | 10-Q filed 2026-10-29 |
| Noncurrent convertible debt | 2026-09-30 | USD 651,087,000 | 10-Q filed 2026-10-29 |
| Noncurrent operating lease liabilities | 2026-09-30 | USD 203,294,000 | 10-Q filed 2026-10-29 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1178670
CUSIP
02043Q107
13F (30d)
589 filings
542 filers
Visit website
Investor relations